Literature DB >> 31974652

Repression of oncogenic cap-mediated translation by 4Ei-10 diminishes proliferation, enhances chemosensitivity and alters expression of malignancy-related proteins in mesothelioma.

Zeeshan Ahmad1, Blake A Jacobson1, Mitchell W McDonald1, Nicolas Vattendahl Vidal1, Gabriel Vattendahl Vidal1, Sierra Chen2, Maxwell Dillenburg3, Aniekan M Okon3, Manish R Patel1, Carston R Wagner3, Robert A Kratzke4,5.   

Abstract

Activated cap-dependent translation promotes cancer by stimulating translation of mRNAs encoding malignancy-promoting proteins. The nucleoside monophosphate Protide, 4Ei-10, undergoes intracellular uptake and conversion by Hint1 to form 7-Cl-Ph-Ethyl-GMP. 7-Cl-Ph-Ethyl-GMP is an analog of cap and inhibits protein translation by binding and sequestering eIF4E thus blocking eIF4E from binding to the mRNA cap. The effects of inhibiting translation initiation by disruption of the eIF4F complex with 4Ei-10 were examined in malignant mesothelioma (MM). In a cell-free assay system, formation of the eIF4F complex was disabled in response to exposure to 4Ei-10. Treatment of MM with 4Ei-10 resulted in decreased cell proliferation, increased sensitivity to pemetrexed and altered expression of malignancy-related proteins. In light of these findings, suppression of translation initiation by small molecule inhibitors like 4Ei-10 alone or in combination with pemetrexed represents an encouraging strategy meriting further evaluation in the treatment of MM.

Entities:  

Keywords:  4Ei-10; 7-Cl-Ph-Ethyl-GMP; Cap-dependent translation; Mesothelioma; ProTide; eIF4E; eIF4G

Mesh:

Substances:

Year:  2020        PMID: 31974652     DOI: 10.1007/s00280-020-04029-9

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  35 in total

Review 1.  Targeting translation: eIF4E as an emerging anticancer drug target.

Authors:  Chunwan Lu; Levi Makala; Daqing Wu; Yafei Cai
Journal:  Expert Rev Mol Med       Date:  2016-01-18       Impact factor: 5.600

Review 2.  eIF4E-mediated translational control of cancer incidence.

Authors:  Peter B Bitterman; Vitaly A Polunovsky
Journal:  Biochim Biophys Acta       Date:  2014-09-28

3.  Small-molecule inhibition of oncogenic eukaryotic protein translation in mesothelioma cells.

Authors:  Esther Z Chen; Blake A Jacobson; Manish R Patel; Aniekan M Okon; Shui Li; Kerry Xiong; Abhishek J Vaidya; Peter B Bitterman; Carston R Wagner; Robert A Kratzke
Journal:  Invest New Drugs       Date:  2014-04-09       Impact factor: 3.850

4.  Structure-guided design, synthesis, and evaluation of guanine-derived inhibitors of the eIF4E mRNA-cap interaction.

Authors:  Xiaoqi Chen; David J Kopecky; Jeff Mihalic; Shawn Jeffries; Xiaoshan Min; Julie Heath; Jeff Deignan; Sujen Lai; Zice Fu; Cristiano Guimaraes; Shanling Shen; Shyun Li; Sheree Johnstone; Stephen Thibault; Haoda Xu; Mario Cardozo; Wang Shen; Nigel Walker; Frank Kayser; Zhulun Wang
Journal:  J Med Chem       Date:  2012-04-18       Impact factor: 7.446

5.  Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer.

Authors:  Andrew C Hsieh; Davide Ruggero
Journal:  Clin Cancer Res       Date:  2010-08-11       Impact factor: 12.531

Review 6.  Targeting the eIF4F translation initiation complex: a critical nexus for cancer development.

Authors:  Jerry Pelletier; Jeremy Graff; Davide Ruggero; Nahum Sonenberg
Journal:  Cancer Res       Date:  2015-01-15       Impact factor: 12.701

7.  Anchimerically Activated ProTides as Inhibitors of Cap-Dependent Translation and Inducers of Chemosensitization in Mantle Cell Lymphoma.

Authors:  Aniekan Okon; JingJing Han; Surendra Dawadi; Christos Demosthenous; Courtney C Aldrich; Mamta Gupta; Carston R Wagner
Journal:  J Med Chem       Date:  2017-09-20       Impact factor: 7.446

8.  4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma.

Authors:  Arpita De; Blake A Jacobson; Mark S Peterson; Joe Jay-Dixon; Marian G Kratzke; Ahad A Sadiq; Manish R Patel; Robert A Kratzke
Journal:  Invest New Drugs       Date:  2017-11-08       Impact factor: 3.850

9.  Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced eIF4E proteasomal degradation.

Authors:  Shui Li; Yan Jia; Blake Jacobson; Joel McCauley; Robert Kratzke; Peter B Bitterman; Carston R Wagner
Journal:  Mol Pharm       Date:  2013-02-04       Impact factor: 4.939

10.  Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide.

Authors:  Blake A Jacobson; Saritha C Thumma; Joseph Jay-Dixon; Manish R Patel; K Dubear Kroening; Marian G Kratzke; Ryan G Etchison; Bruce W Konicek; Jeremy R Graff; Robert A Kratzke
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

View more
  3 in total

1.  A Phosphoramidate Strategy Enables Membrane Permeability of a Non-nucleotide Inhibitor of the Prolyl Isomerase Pin1.

Authors:  Daniel M C Schwarz; Sarah K Williams; Maxwell Dillenburg; Carston R Wagner; Jason E Gestwicki
Journal:  ACS Med Chem Lett       Date:  2020-08-10       Impact factor: 4.345

Review 2.  The plasticity of mRNA translation during cancer progression and therapy resistance.

Authors:  Lucilla Fabbri; Alina Chakraborty; Caroline Robert; Stéphan Vagner
Journal:  Nat Rev Cancer       Date:  2021-08-02       Impact factor: 60.716

3.  4Ei-10 interdiction of oncogenic cap-mediated translation as therapy for non-small cell lung cancer.

Authors:  Blake A Jacobson; Zeeshan Ahmad; Sierra Chen; Gabriella Waldusky; Maxwell Dillenburg; Emilia Stoian; Daniel A Cambron; Anil J Patel; Manish R Patel; Carston R Wagner; Robert A Kratzke
Journal:  Invest New Drugs       Date:  2020-11-23       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.